Eylea leads the way to strong third quarter for Regeneron

Regeneron Pharmaceuticals (Nasdaq: REGN) has posted upbeat financial results for the third quarter of 2018, with revenues of $1.6 billion, a little under many analysts’ expectations, but still 11% higher than the same period last year.

Following Generally Accepted Accounting Principles (GAAP), net income rose more than 50%, at $595 million, or $5.17 per share.

The firm’s strong performance was driven by a 7% rise in US sales of Eylea (aflibercept), partnered with Bayer (BAYN: DE), to $1 billion, and an 11% rise globally, to $1.68 billion.